Trial · NCT07235930
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
NCT07235930, Phase 3, Recruiting, Zhejiang Cancer Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer. Trials, record NCT07235930. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07235930
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
- NCT number
- NCT07235930
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 292 participants, estimated
- Lead sponsor
- Zhejiang Cancer Hospital
- Conditions
- Non-Resectable Pancreas Carcinoma
- Interventions
- Sequential AG and mFOLFOX in Combination With Serplulimab and Bevacizumab, AG chemotherapy
- First posted
- 2025-11-19
- Last updated
- 2025-11-19
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | up to 36 months | The time interval between the start date of study drug and the date of death (any cause) |
| Secondary | Objective response rate(ORR) | up to 12 months | The number of cases in which tumor size is reduced to PR or CR / the total number of evaluable cases (%) |
| Secondary | Progression-free survival (PFS) | up to 12 months | Refers to the date from the date of admission to the date of the first progression of disease or death of any cause, using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). |
| Secondary | Disease control rate (DCR) | up to 12 months | Percentage of confirmed cases including complete remission (CR), partial remission (PR) and disease stability (SD) among patients with evaluable efficacy |
| Secondary | Incidence of Treatment-Emergent Adverse Events | up to 3 months after enrollment or study close | The safety and tolerability profile will be assessed by the incidence of TEAEs. The number and percentage of participants experiencing any TEAE, treatment-related AEs, serious AEs (SAEs), and AEs leading to discontinuation will be summarized. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. |
| Secondary | Level of Protein Biomarkers in Tumor Tissue | Baseline | Protein expression levels in pre-treatment tumor tissue will be quantified using mass spectrometry-based proteomics and immunofluorescence staining. The association between the baseline levels of specific protein biomarkers (e.g., target antigen, immune markers) and Objective Response Rate will be evaluated. |
| Other | Dynamics of Peripheral Blood Biomarkers | Baseline, Day 29 of Cycle 1 , at the time of first and second tumor assessment, and at disease progression. | Changes in blood-based biomarker levels from baseline will be measured. Peripheral blood samples will be used for: 1) Immunophenotyping: The frequency of key immune cell subsets (e.g., CD4+/CD8+ T cells) in PBMCs will be analyzed by flow cytometry. 2) Plasma Multi-omics: Proteins and metabolites will be profiled using proteomics and metabolomics platforms, respectively. Metrics will include the mean change from baseline at each timepoint and the correlation of these changes with clinical response. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07235930
GET https://conductscience.org/api/trials/v1/NCT07235930/registered